Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma.
Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Research Abstract Details
Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Publishing Authors By Initials
Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Journal Published:
PUBLICATION TYPE: Letter
Journal: Leukemia & lymphoma
VOLUME: 49
Page Numbers: 359-61
Journal Abbreviation: Leuk. Lymphoma
ISSN: 1042-8194
DAY: 30
MONTH: Feb
YEAR: 2008
Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 9007422
Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma.
AFFILIATION: Department of Medicine, Pathology, Radiation Oncology, Pharmacology and Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA.
Country: England
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Leuk Lymphoma
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Inhibition of the mammalian target of rapamycin mTOR in a case of refractory primary cutaneous anaplastic large cell lymphoma Related Publications